[16] When combined with inhibitors of either the phosphoinositide 3-kinase (PI3K) or the MAPK signaling pathway, AMG 232 demonstrated synergy in cell death across various TP53-WT melanoma cell lines [17]. The gene discussed is TP53; the disease is melanoma.